Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

Residents from the RheumMadness Leadership Team: Michael Macklin, MD, PharmD; Ben Kellogg, MD; Lauren He, MD; & David Leverenz, MD  |  February 8, 2022

According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

Lab Study Suggests Zinc May Worsen Rheumatoid Arthritis

Marilynn Larkin  |  January 22, 2022

NEW YORK (Reuters Health)—Zinc supplementation may exacerbate rheumatoid arthritis (RA), new laboratory data suggest. In monocytes from patients with RA, researchers found high concentrations of intracellular zinc, which regulates immune responses by affecting signaling pathways, according to a report in Science Signaling.1 They also found increased expression of Zip8, a zinc-specific importer, in peripheral and…

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

Thomas R. Collins  |  December 9, 2021

Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Tofacitinib Yields Rapid & Sustained Improvement in JIA

Reuters Staff  |  December 3, 2021

NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…

Advances in Rheumatology & Challenges that Remain Spotlighted in ACR Convergence 2021 Closing Session

Vanessa Caceres  |  December 2, 2021

The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.

Management of Adults with JIA: Uveitis, MAS & More

Mary Beth Nierengarten  |  December 2, 2021

Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.

What Orthopedists Want Rheumatologists to Know: Surgical Treatment for Foot & Ankle Arthritis

Mary Beth Nierengarten  |  December 2, 2021

Surgical options to relieve pain associated with foot and ankle arthritis are discussed.

Heart to Heart: Cardiovascular Disease in Autoimmune Conditions

Jason Liebowitz, MD, FACR  |  December 2, 2021

During the ACR Convergence 2021 Review Course, Joan Bathon, MD, discussed cardiovascular manifestations of autoimmune diseases, including rheumatoid arthritis.

FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

Thomas R. Collins  |  December 1, 2021

ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 74
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences